This study aims to learn about the cardiovascular complications of COVID-19 and the clinical, laboratory and imaging predictors of myocardial injury and dysfunction resulting from SARS-CoV-2 infection, with a view to developing a plan of measures to reduce the risk of death from COVID-19 in people with cardiovascular disease. This is an integrative literature review carried out in electronic databases: PubMed, LILACS, Embase, Scopus, WOS and CINAHL, with the descriptors: Cardiovascular system; risk factors; Comorbidity; Cardiovascular diseases; Heart injury and Covid-19 with the inclusion of original studies in the period 2019-2022. The search resulted in 44 articles, in English, which highlighted the risk factors and/or comorbidities associated with cardiovascular complications potentiated by COVID-19; prognosis and increased mortality from cardiovascular causes induced by COVID-19. It is concluded that cardiovascular impairment can determine the severity and contribute to death in individuals with COVID-19, potentiated by pre-existing cardiovascular disease or cardiometabolic risk factors, affecting the need for ventilatory and hemodynamic support.
Background: The roles of cytokines and chemokines in the pathogenesis of Chagas cardiomyopathy (CC) have been proposed, yet their clinical significance with respect to conduction disturbances and left ventricular ejection fraction (LVEF) remains unclear. Aim: The objective of this study was to analyze the associations between cytokine levels and systolic function, comparing patients with preserved and reduced ejection fractions. As a secondary objective, we evaluated whether differences were present in cytokine levels within the subgroup with preserved ejection fraction, depending on the presence or absence of intraventricular conduction disturbances. Methods: We conducted an analytical cross-sectional study involving patients with Chagas disease and a healthy control group. Among patients with Chagas disease, those with preserved (>50%) and reduced ( 50%), and 50% (n = 22) had decreased LVEF (≤35%). No significant differences in cytokine concentrations were observed between patients with preserved and reduced LVEF for TNF-α (19.74 ± 8.32 vs. 22.23 ± 6.40 pg/mL; p = 0.189), IL-6 (2.17 ± 2.41 vs. 5.40 ± 6.40 pg/mL; p = 0.145), IL-2 (2.61 ± 1.05 vs. 2.97 ± 1.79 pg/mL; p = 0.481), MCP-1 (214.18 ± 96.99 vs. 183.83 ± 63.21 pg/mL; p = 0.481) and IFN-γ (9.04 ± 4.90 vs. 7.64 ± 3.78 pg/mL; p = 0.372). Within the subgroup with preserved LVEF (n = 22), those with conduction disorders (n = 10) exhibited higher levels of IL-10 (24.49 vs. 9.83 pg/mL; q = 0.009), IL-12p70 (13.20 vs. 9.02 pg/mL; q = 0.027), IL-2 (2.70 vs. 2.07 pg/mL; q = 0.023), IL-15 (7.09 vs. 3.36 pg/mL; q = 0.018), MIP1α (10.33 vs. 3.35 pg/mL; q = 0.014) and IFN-γ (10.83 vs. 7.25 pg/mL; q = 0.005), compared to those without conduction disorders (n = 12). Notably, patients with CD and preserved LVEF (>50%) without conduction disturbances presented cytokine profiles similar to those of seronegative healthy controls with LVEF ≥ 50%. Conclusions: Elevated levels of specific cytokines were associated with conduction disturbances in patients with preserved LVEF. Despite this finding, a causal relationship cannot be established, and future studies are needed to explore their prognostic or therapeutic significance.
Objetivo: Identificar o perfil epidemiológico dos vírus HBV e HCV, considerando as variáveis raça, faixa etária, sexo e os mecanismos de infecção, nas regiões Norte e Nordeste de 2014 a 2018. Métodos: Trata-se de um estudo observacional, descritivo, do tipo transversal, com dados secundários, coletados no banco de dados do Sistema de Informação de Agravos de Notificações (SINAN). Resultados: Verificou-se a predominância em indivíduos adultos, na faixa etária de 20 a 59 anos de idade, pardos, com predominância do sexo masculino, sendo a via sexual, a principal forma de transmissão em ambos, não devendo dispensar atenção entre os demais fatores de riscos. Conclusão: Concluiu-se que, a prevalência da infecção pelo HBsAg e HCV nas regiões estudadas, demonstrou que, ainda é muito comum a ausência no uso de métodos eficazes que previnem a ocorrência não somente das hepatites virais B e C, mas de um amplo número de infecções sexualmente transmissíveis. Esses achados apontaram para a necessidade de esclarecimento da população quanto às formas de transmissão, tratamento e prevenção das hepatites virais, com adequação nas ações de intervenções baseada nas necessidades específicas de cada região.
Passive immunotherapy has been evaluated in many infections. The present study aims to evaluate purified F(ab’) 2 fraction of equine hyperimmune IgG (anti-SARS-CoV-2) in the treatment of coronavirus lung disease. Patients with coronavirus disease of 2019 (COVID-19) with World Health Organization (WHO) score 3, 4 or 5 up to 72 hours of evolution from the onset of symptoms were included. They were randomly assigned to anti-SARS-CoV-2 or placebo. Follow-up was performed for 28 days to assess efficacy, safety, pharmacokinetics, detection of anti-horse antibodies, circulating cytokines and determination of anti-SARS neutralizing activity. The 20 initial patients (44±14 years) were included. On the third day of treatment there was an improvement (P=0.02) in arterial saturation (95±1.6 vs. 93±2.5%) with increasing differences over time between treatments (day 8: 97±0.1 vs. 94±0.3%). The length of oxygen therapy treatment was 2±0.8 vs. 3±0.9 (0.048) in patients falling within WHO 5 category (no difference to WHO 4). Mean hospitalization was 13±2.5 vs. 14±0.8 days (P=0.095) and time to clinical improvement was 2±0.5 vs. 3±0.9 days (P=0.048) in patients with initial 5 WHO category, with no differences to patients who started with WHO stage 4. The time to nasal swab negativization was 10±2.1 vs. 12±0 day (P=0.015). No adverse reactions or intercurrences were detected. All patients presented heterophile antibodies without clinical correlate. The new treatment shows improvement in arterial saturation (days 3 to 12), and a decrease on detectable viral RNA (days 8 to 11) with good pharmacokinetic and safety profile.
Tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a manageable disease, and discontinuation has become a feasible goal for many patients. However, molecular relapse after TKI cessation remains a challenge. This study investigated factors influencing molecular relapse-free survival (MRFS) in a real-world cohort of CML patients undergoing TKI discontinuation, focusing on clinical, molecular, and immune-related variables. Traditional prognostic tools, such as the Sokal score, showed limited capacity to predict relapse risk in this context. Instead, total treatment duration and depth of molecular response emerged as critical predictors, with longer therapy and deeper remission associated with improved outcomes. A key novel finding was the prognostic relevance of cytokine profiles, particularly interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1). These cytokines were strong predictors of relapse in a decision tree model that achieved high specificity and positive predictive value in an independent validation cohort. Notably, lower IL-6 and MCP-1 levels were associated with increased relapse risk, suggesting reduced immune surveillance may contribute to recurrence. Integrating cytokine signatures with molecular markers improved prognostic accuracy, supporting immune biomarkers as complements to established clinical parameters. These findings underscore the complexity of relapse mechanisms and the need for individualized risk assessment when considering TKI discontinuation.